Tabata Tsutomu, Takeshima Nobuhiro, Nishida Hidetaka, Hirai Yasuo, Hasumi Katsuhiko
Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Anticancer Res. 2003 May-Jun;23(3C):2885-90.
To determine whether neoadjuvant chemotherapy would improve disease control and clinical outcome of patients with locally advanced cervical cancer undergoing radiotherapy.
Sixty-one patients with primary invasive squamous cell carcinoma of the cervix of stage IIIB or IVA were randomized to receive either three courses of chemotherapy followed by radiotherapy (CT + RT) or radiotherapy alone (RT). The chemotherapy regimen consisted of bleomycin, vincristine, mitomycin and cisplatin (BOMP). The radiotherapy was carried out by the use of a combination of external beam radiation and intracavitary brachytherapy.
The response rate of the chemotherapy (complete or partial response) in the CT + RT group was 72% (3 + 20 out of 32). The 5-year survival rates were 52% in RT group and 43% in the CT + RT group with no significant difference. Recurrence outside the irradiated field occurred in 17% (5 out of 29) in the RT group, whereas it was 25% (8 out of 32) in the CT + RT group.
Despite the high response rate of BOMP chemotherapy, the combination (CT + RT) failed to improve the survival of patients with locally advanced cervical cancer when compared with radiotherapy alone. It was also noteworthy that the incidence of distant metastasis was not reduced by the use of neoadjuvant chemotherapy.
确定新辅助化疗是否能改善接受放疗的局部晚期宫颈癌患者的疾病控制情况和临床结局。
61例ⅢB期或IVA期原发性宫颈浸润性鳞状细胞癌患者被随机分为两组,一组先接受三个疗程的化疗,然后进行放疗(CT + RT),另一组仅接受放疗(RT)。化疗方案由博来霉素、长春新碱、丝裂霉素和顺铂(BOMP)组成。放疗采用外照射和腔内近距离放疗相结合的方式。
CT + RT组化疗的缓解率(完全或部分缓解)为72%(32例中有3例完全缓解和20例部分缓解)。RT组的5年生存率为52%,CT + RT组为43%,差异无统计学意义。RT组29例中有17%(5例)出现照射野外复发,而CT + RT组32例中有25%(8例)出现照射野外复发。
尽管BOMP化疗缓解率高,但与单纯放疗相比,联合治疗(CT + RT)未能提高局部晚期宫颈癌患者的生存率。同样值得注意的是,新辅助化疗并未降低远处转移的发生率。